Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANZ Olive immunotherapy tolerability (up-dosing phase)
2011-004852-20Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Dec 2011
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Alutard Avanz SQ in allergic rhinoconjunctivitis (ARC), allergic rhinitis (AR) and asthma, sponsored by ALK-Abelló. Primary endpoint: Tolerability (adverse reactions). Started Dec 2011; status: completed.
02
Drugs
Alutard Avanz SQ
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic rhinitis (AR)asthma
Beyond the preview
Go deeper on 2011-004852-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004852-20.